I started my career as a Product Executive, Product Management Department (PMD) at Labaid Pharmaceuticals Ltd., where I was responsible for managing a mixed portfolio of products. Specifically, I looked after Bisoprolol, Pregabalin, Azithromycin, Clonazepam, and Pantoprazole. After gaining almost two years of valuable experience, I transitioned to ACI Pharmaceuticals Ltd. In my role at ACI, I focused on the antibiotic portfolio, which included Linezolid, Ceftriaxone, and Amoxicillin.Following my time at ACI, I joined Healthcare Pharmaceuticals Ltd. Now I am working as a Product Manager (Assistant Manager) in the Strategic Marketing Department (SMD). Here, I have been entrusted with two prestigious segments: Oncology+ Hematology and Virology+Rheumatology . In the Oncology+Hematology segment, I am responsible for 14 brands, namely Filgrastim (Neufil), Paclitaxel (Paxel), Rituximab (Recelbia), Eltrombopag (Idiopag), Gemcitabine (Gembine), Zoledronic Acid (Zoclast), Etoposide (Toposide), Calcium Folinate (Leufol), Methotrexate (Trexall), Doxorubicin (Adribin), Dasatinib (Danib), Gefitinib (Genib), Fluorouracil (Drucil), and Abiraterone (Zyterone). In the Virology+ Rheumatology segment, I am responsible for 5 brands: Tenofovir (Protovir), Sofosbuvir and Velpatasvir (Velatas), and Peginterferon (Pegferon), Rituximab (Recelbia) & Trexall (Methotrexate).During my tenure at Healthcare Pharmaceuticals Ltd., I have successfully launched 6 molecules: Etoposide (Toposide), Calcium Folinate (Leufol), Methotrexate (Trexall), Dasatinib (Danib), Gefitinib (Genib), and Abiraterone (Zyterone). Recently I have launched Opocan (Topotecan) & Altina (Lapatinib). Additionally, I am currently preparing to launch several other promising molecules in the near future.